AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 151 min read$ONC

Ball Titus B. sold $43K of ONC

Ball Titus B. (Principal Accounting Officer) sold 169 shares of BeOne Medicines Ltd. (ONC) at an average of $257.20 ($256.39–$257.53) across 2 trades on 2026-06-11.

Original reporting
SEC EDGAR · Ball Titus B.
Published Jun 15, 2026, 9:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ONC
Neutral
medium confidence
Mentioned
$ONC
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

This provides a fresh, primary-source datapoint on insider selling activity, but it does not include any new corporate, clinical, or regulatory development.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a sustained repricing without additional catalysts.

03

What to watch

The filing shows the insider ended with 0 shares, but it does not disclose motives, compensation context, or whether other insiders/owners are buying.

Relevance 3/10Novelty 8/10Timing: filed 2026-06-15 for a 2026-06-11 insider sale

Background

The article is an SEC Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCNeutralMedium confidence
Context

BeOne Medicines insider Ball Titus B. sold $43,466.56 of ONC shares via an open-market sale on 2026-06-11, leaving 0 shares.

Expected impact

Likely limited near-term impact; any reaction should fade unless followed by additional disclosures or fundamental news.

Evidence & confidence

The filing is a primary-source insider transaction, but the article provides no new business, guidance, or regulatory/clinical catalyst—only a sale by an accounting officer.

Market effects

Sector

Minimal; single insider sale without accompanying company-specific operational updates.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be planned for liquidity/taxes; the absence of a stated 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • issuer
    BeOne Medicines Ltd.

    Company whose insider transaction is disclosed on SEC Form 4.

  • insider
    Ball Titus B.

    Principal Accounting Officer who sold ONC shares in an open-market transaction.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ONC insider trading history →

Related articles

SEP 1
$ONCHighAI 9/10

FDA Approval Marks A Turning Point For BeOne Medicines (ONC)

BeOne Medicines (ONC) announced FDA approval for TEVIMBRA in combination with ZIIHERA and chemotherapy for HER2-positive gastroesophageal adenocarcinoma. The approval is based on Phase 3 trial data showing a median survival of 26.4 months. The company reported Q2 2026 revenue of $1.7 billion, up 30% YoY, and raised full-year revenue guidance to $6.6B-$6.8B. However, a Phase 3 study for zanubrutinib-sonrotoclax combination did not meet its primary endpoint.

yahoo.com2 min
SEP 1
$ALCMedAI 8/10

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

tradingview.com3 min
SEP 1
$ALCLow

Trump Expands Drug Pricing Agreements With 9 Drugmakers— RFK Jr. Says President Called ‘Every Hour’ to En

President Trump announced drug pricing agreements with nine pharmaceutical companies, including Alcon (ALC), BeOne (ONC), BridgeBio (BBIO), and Teva (TEVA). The deals require discounts on outpatient drugs for Medicaid and $19.6B in U.S. manufacturing investments. This expands the total to 26 companies, covering 90% of the U.S. market. The White House estimates $529B in savings over a decade.

benzinga.com2 min
AUG 31
$ONCHighAI 8/10

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines reported positive Phase 3 trial results for ZIIHERA (zanidatamab) plus chemotherapy, with and without TEVIMBRA (tislelizumab), in HER2+ gastroesophageal cancer. The study met its primary endpoint, showing statistically significant overall survival benefits. The FDA recently approved these regimens for first-line treatment. BeOne has rights to ZIIHERA in Asia, Australia, and New Zealand.

leaderpost.com2 min